Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa.
Rotavirus Vaccine
444563/022
NCT00263666
Infections, Rotavirus
Phase 2
 
An annotated case report form is not available for this study. A blank case report form will be provided. A link to Clinicaltrials.gov and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014

Powered by ideaPoint, Inc.